<DOC>
	<DOCNO>NCT01021150</DOCNO>
	<brief_summary>Primary Objective : - To determine maximum tolerate dose base incidence dose limit toxicity maximum administer dose ombrabulin combination cisplatin administer every 3 week patient advance solid tumor . Secondary Objectives : - To assess overall safety profile combination therapy . - To characterize pharmacokinetic profile ombrabulin , active metabolite RPR 258063 , cisplatin combination . - To evaluate anti-tumor activity combination therapy .</brief_summary>
	<brief_title>Dose Escalation , Safety Pharmacokinetic Study AVE8062 Combined With Cisplatin Patients With Solid Tumors</brief_title>
	<detailed_description>The duration study patient include 4-week screening phase , 21-day study treatment cycle , end treatment visit follow-up period 30 day last infusion ombrabulin . The patient continue treatment disease progression , unacceptable toxicity , patient 's refusal treatment .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Inclusion criterion : Advanced solid tumor become refractory conventional treatment standard therapy exist . Exclusion criterion : Eastern Cooperative Oncology Group performance status ≥ 2 . Concurrent treatment anticancer therapy Male female patient agree contraception . Washout period le 28 day prior anticancer therapy ( chemotherapy , target agent , immunotherapy radiotherapy ) investigational treatment , except nitrosoureas , mitomycin may use 42 day prior first cycle.No washout period require hormonal therapy discontinue first cycle . Not recover previous therapy ( radiation , surgery , medication ) . Adverse event relate previous therapy must National Cancer Institute Common Terminology Criteria ( NCICTCAE V3.0 ) grade≤1 ( alopecia≤grade 2 ) screening return subject 's baseline prior recent previous therapy . Symptomatic brain metastasis carcinomatous leptomeningitis . Other serious illness medical condition control adequate treatment Previous cumulative carboplatin dose high 3,000 mg/m2 cisplatin high 600 mg/m2 . Patients whose disease progress recur less 6 month completion previous platinum contain chemotherapy Known platinum compound hypersensitivity . Neuropathy ototoxicity due previous platinum chemotherapy . Inadequate organ function Documented medical history myocardial infarction , document angina pectoris , arrhythmia especially severe conduction disorder second third degree atrioventricular block , stroke , history arterial venous thromboembolism within past 180 day require anticoagulant . Patient leave ventricular ejection fraction &lt; 50 % echocardiography . Patients baseline QTc interval &gt; 0.45 , family history Long QT Syndrome . Patient uncontrolled hypertension patient organ damage relate hypertension leave ventricular hypertrophy grade 2 ocular fundscopic change kidney impairment . Patients grow vessel disease ( eg agerelated macular degeneration , diabetic retinopathy , rheumatoid arthritis ) , ongoing wound heal process . Patients enrol study least 28 day surgery 12lead Electrocardiogram : ST Twave change suggest ischemia Hypertension define systolic blood pressure ( BP ) &gt; 140 mmHg diastolic BP &gt; 90 mmHg two repeat measurement 30 minute interval . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>